William J. Peters Sells 10,282 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) CFO William J. Peters sold 10,282 shares of the business’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $44.23, for a total transaction of $454,772.86. Following the completion of the transaction, the chief financial officer now directly owns 94,103 shares in the company, valued at approximately $4,162,175.69. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Amphastar Pharmaceuticals Trading Down 2.1 %

AMPH traded down $0.88 during trading on Friday, reaching $41.57. The company had a trading volume of 397,098 shares, compared to its average volume of 416,159. The company has a quick ratio of 1.72, a current ratio of 2.18 and a debt-to-equity ratio of 0.88. The business has a 50 day simple moving average of $40.52 and a 200-day simple moving average of $44.61. The stock has a market cap of $2.03 billion, a P/E ratio of 14.69, a PEG ratio of 0.77 and a beta of 0.79. Amphastar Pharmaceuticals, Inc. has a 52 week low of $36.56 and a 52 week high of $67.66.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings results on Wednesday, May 8th. The company reported $0.93 earnings per share for the quarter, topping the consensus estimate of $0.73 by $0.20. Amphastar Pharmaceuticals had a return on equity of 29.17% and a net margin of 22.88%. The firm had revenue of $171.84 million for the quarter, compared to the consensus estimate of $171.13 million. On average, equities analysts anticipate that Amphastar Pharmaceuticals, Inc. will post 3.59 EPS for the current fiscal year.

Institutional Trading of Amphastar Pharmaceuticals

Large investors have recently made changes to their positions in the stock. Principal Securities Inc. bought a new stake in Amphastar Pharmaceuticals during the 4th quarter valued at $34,000. YHB Investment Advisors Inc. purchased a new position in shares of Amphastar Pharmaceuticals during the first quarter valued at $27,000. Quadrant Capital Group LLC increased its stake in shares of Amphastar Pharmaceuticals by 27.8% during the fourth quarter. Quadrant Capital Group LLC now owns 1,026 shares of the company’s stock valued at $63,000 after buying an additional 223 shares during the period. Innealta Capital LLC bought a new stake in shares of Amphastar Pharmaceuticals in the second quarter valued at about $55,000. Finally, Blue Trust Inc. lifted its stake in Amphastar Pharmaceuticals by 23.9% in the second quarter. Blue Trust Inc. now owns 1,604 shares of the company’s stock worth $70,000 after acquiring an additional 309 shares during the period. 65.09% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

AMPH has been the subject of a number of research analyst reports. Needham & Company LLC restated a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Wednesday, May 22nd. Piper Sandler reaffirmed an “overweight” rating and issued a $71.00 price objective on shares of Amphastar Pharmaceuticals in a research note on Thursday, June 27th. Finally, StockNews.com upgraded Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, May 13th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, Amphastar Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $64.67.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.